Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1974 1
1982 1
1983 2
1986 2
1988 1
1989 4
1990 1
1991 1
1992 2
1994 1
1995 8
1996 3
1997 2
1998 1
1999 1
2000 3
2001 1
2002 3
2003 2
2004 6
2005 4
2006 3
2007 6
2008 3
2009 1
2010 5
2011 9
2012 3
2013 5
2014 3
2015 8
2016 6
2017 8
2018 2
2019 1
2020 5
2021 3
2022 5
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215938 Free article. Review.
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting do …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorit …
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e558-e631. doi: 10.1161/CIR.0000000000000937. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215931 Free article. Review. No abstract available.
Classification, Epidemiology, and Global Burden of Cardiomyopathies.
McKenna WJ, Maron BJ, Thiene G. McKenna WJ, et al. Circ Res. 2017 Sep 15;121(7):722-730. doi: 10.1161/CIRCRESAHA.117.309711. Circ Res. 2017. PMID: 28912179 Review.
In the past 25 years, major advances were achieved in the nosography of cardiomyopathies, influencing the definition and taxonomy of this important chapter of cardiovascular disease. ...Novel cardiomyopathies have been discovered (arrhythmogenic, restrictive, and noncompac …
In the past 25 years, major advances were achieved in the nosography of cardiomyopathies, influencing the definition and taxonomy of …
Noonan syndrome and clinically related disorders.
Tartaglia M, Gelb BD, Zenker M. Tartaglia M, et al. Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):161-79. doi: 10.1016/j.beem.2010.09.002. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 21396583 Free PMC article. Review.
Cardinal features include postnatally reduced growth, distinctive facial dysmorphism, congenital heart defects and hypertrophic cardiomyopathy, variable cognitive deficit and skeletal, ectodermal and hematologic anomalies. ...
Cardinal features include postnatally reduced growth, distinctive facial dysmorphism, congenital heart defects and hypertrophic ca
State-of-the-art document on optimal contemporary management of cardiomyopathies.
Seferović PM, Polovina M, Rosano G, Bozkurt B, Metra M, Heymans S, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Olivotto I, Rapezzi C, Linhart A, Corrado D, Tschöpe C, Milinković I, Bayes Genis A, Filippatos G, Keren A, Ašanin M, Krljanac G, Maksimović R, Skouri H, Ben Gal T, Moura B, Volterrani M, Abdelhamid M, Lopatin Y, Chioncel O, Coats AJS. Seferović PM, et al. Eur J Heart Fail. 2023 Nov;25(11):1899-1922. doi: 10.1002/ejhf.2979. Epub 2023 Sep 24. Eur J Heart Fail. 2023. PMID: 37470300 Review.
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation o …
Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-b …
Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature.
Bayonas-Ruiz A, Muñoz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Bayonas-Ruiz A, et al. ESC Heart Fail. 2023 Feb;10(1):8-23. doi: 10.1002/ehf2.14142. Epub 2022 Oct 1. ESC Heart Fail. 2023. PMID: 36181355 Free PMC article. Review.
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical characteristics of patients with hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: A systematic review and meta-analysis …
AIMS: The aim of this study was to synthesize the evidence on the effect of the current therapies over the pathophysiological and clinical c …
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Guttmann OP, et al. Heart. 2014 Mar;100(6):465-72. doi: 10.1136/heartjnl-2013-304276. Epub 2013 Sep 7. Heart. 2014. PMID: 24014282 Review.
OBJECTIVE: To critically review current literature on atrial fibrillation (AF) and thromboembolism in hypertrophic cardiomyopathy (HCM) and meta-analyse prevalence and incidence. ...Overall prevalence of thromboembolism in HCM patients with AF was 27.09% (95% CI 20. …
OBJECTIVE: To critically review current literature on atrial fibrillation (AF) and thromboembolism in hypertrophic cardiomyopathy
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, Bronis K, Papageorgiou N, Chow A, Rowland E, Lowe M, Segal OR, Lambiase PD. Providencia R, et al. Heart. 2016 Oct 1;102(19):1533-43. doi: 10.1136/heartjnl-2016-309406. Epub 2016 May 27. Heart. 2016. PMID: 27234160 Review.
OBJECTIVE: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of stroke. ...Freedom from AF/atrial tachycardia relapse was higher in patients without HCM (after a single procedure: 38.7% HCM vs 49.8% controls, …
OBJECTIVE: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of strok …
Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review.
Moore JC, Trager L, Anzia LE, Saliba W, Bassiouny M, Bhargava M, Chung M, Desai M, Garberich R, Lever H, Lindsay BD, Sengupta J, Tchou P, Wazni O, Wilkoff BL. Moore JC, et al. Pacing Clin Electrophysiol. 2018 Apr;41(4):396-401. doi: 10.1111/pace.13310. Epub 2018 Mar 12. Pacing Clin Electrophysiol. 2018. PMID: 29450893 Review.
BACKGROUND: Limited medical options are available for rhythm control in patients with atrial fibrillation (AF) and hypertrophic cardiomyopathy (HCM). There are no published reports of dofetilide use in this population. ...Of the 25 patients, 21 were discharge …
BACKGROUND: Limited medical options are available for rhythm control in patients with atrial fibrillation (AF) and hypertrophic ca
Transthyretin Cardiac Amyloidosis.
Mankad AK, Shah KB. Mankad AK, et al. Curr Cardiol Rep. 2017 Aug 24;19(10):97. doi: 10.1007/s11886-017-0911-5. Curr Cardiol Rep. 2017. PMID: 28840452 Review.
PURPOSE OF REVIEW: Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed. ...RECENT FINDINGS: Wild-type transthyretin (ATTRwt) protein causes cardiac a …
PURPOSE OF REVIEW: Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertens …
128 results